A groundbreaking AI algorithm developed by Mount Sinai researchers can now accurately predict heart disease risk with unprecedented precision. The technology, called Viz HCM, assigns numeric probabilities to help identify patients with hypertrophic cardiomyopathy (HCM) before critical symptoms develop. By providing more meaningful risk assessments, the algorithm could revolutionize early cardiac intervention and potentially prevent serious complications like sudden cardiac death. This innovation represents a significant advancement in using artificial intelligence to improve personalized medical diagnostics and patient care.
April 24, 2025
AI algorithm can help identify high-risk heart patients: Study
"This
is an important step forward in translating novel deep-learning algorithms into
clinical practice" - Joshua Lampert, Mount Sinai
Tuesday
said they have calibrated an artificial intelligence (AI) algorithm to quickly
and more specifically identify patients with the condition and flag them as
high risk for greater attention during doctor’s appointments.
Key
Points
1 AI
algorithm Viz HCM provides precise heart disease risk probabilities
2 Helps
identify high-risk patients before symptoms emerge
3 FDA-approved
technology for detecting hypertrophic cardiomyopathy
4 Potential
to prevent serious cardiac complications
The
algorithm, known as Viz HCM, had previously been approved by the Food and Drug
Administration (FDA) for the detection of HCM on an electrocardiogram (ECG).
The Mount
Sinai study, published in the journal NEJM AI, assigns numeric probabilities to
the algorithm’s findings.
For
example, while the algorithm might previously have said "flagged as
suspected HCM" or "high risk of HCM," the Mount Sinai study
allows for interpretations such as, "You have about a 60 percent chance of
having HCM," said Joshua Lampert, Director of Machine Learning at Mount
Sinai Fuster Heart Hospital.
As a
result, patients who had not previously been diagnosed with HCM may be able to
get a better understanding of their individual disease risk, leading to a
faster and more individualized evaluation, along with treatment to potentially
prevent complications such as sudden cardiac death, especially in young patients.
“This is
an important step forward in translating novel deep-learning algorithms into
clinical practice by providing clinicians and patients with more meaningful
information. Clinicians can improve their clinical workflows by ensuring the
highest-risk patients are identified at the top of their clinical work list
using a sorting tool,” said Lampert, Assistant Professor of Medicine
(Cardiology, and Data-Driven and Digital Medicine) at the Icahn School of
Medicine at Mount Sinai.
HCM
impacts one in 200 people worldwide and is a leading reason for heart
transplantation. However, many patients don’t know they have the condition
until they have symptoms and the disease may already be advanced.
“This
study reflects pragmatic implementation science at its best, demonstrating how
we can responsibly and thoughtfully integrate advanced AI tools into real-world
clinical workflows,” said co-senior author Girish N Nadkarni, Chair of the
Windreich Department of Artificial Intelligence and Human Health and Director of
the Hasso Plattner Institute for Digital Health.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment